Celltran clinches £1m funding:
This article was originally published in Clinica
Executive Summary
UK wound care therapy developer Celltran is accelerating the development and commercialisation of its core products after securing £1m ($2m) in additional funding. The Sheffield-based company said its Ulcodress plus (for treating static chronic wounds) and Cryoskin (for treating burns) products are poised to enter the market. It already has a revenue-generating product, Myskin, available in the UK, while Lyphoderm, a wound care product made from freeze-dried donor skin cells, is about to enter phase III trials. The financing round was led by Yorkshire Fund Managers and included contributions from all Celltran's existing shareholders including South Yorkshire Investment Fund, Innogetics, Biofusion, White Rose Technology Seedcore Fund and PUK Ventures.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.